Karuna Therapeutics, Inc.
(NASDAQ : KRTX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson
0.13%129.840.7%$918.23m
PFEPfizer Inc.
0.17%36.560.9%$718.70m
MRKMerck & Co., Inc.
0.37%82.810.7%$597.72m
ABBVAbbVie, Inc.
-0.73%71.082.3%$548.43m
BMYBristol-Myers Squibb Company
0.30%49.891.4%$447.22m
LLYEli Lilly and Company
0.80%112.001.0%$327.81m
AZNAstraZeneca PLC Sponsored ADR
1.14%43.621.2%$144.74m
NVSNovartis AG Sponsored ADR
-0.12%86.420.2%$132.28m
GSKGlaxoSmithKline plc Sponsored ADR
0.05%41.120.3%$82.22m
NVONovo Nordisk A/S Sponsored ADR Class B
0.18%51.060.1%$69.48m
SNYSanofi Sponsored ADR
0.23%44.400.2%$54.24m
LCILannett Company, Inc.
-1.38%13.5835.6%$51.16m
AKTXAkari Therapeutics Plc Sponsored ADR
-4.48%1.921.6%$2.13m
EPIXESSA Pharma Inc
2.21%3.010.1%$0.19m

Company Profile

Karuna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It engages in business of research and development of therapies utilizing muscarinic cholinergic receptors to treat psychosis and cognitive impairment in numerous central nervous system disorders. The company develops treatments for people afflicted with schizophrenia. Karuna Therapeutics was founded in July 2009 by Andrew Miller, Eric Elenko and Peter Jeffrey Conn and is headquartered in Boston, MA.